Moderna Financial Ratios
MRNA / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 1.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-32.6%
ROE ranks in the bottom 25% among Health Care companies
Profit Margin
-145.2%
Net Income / Revenue
Asset Turnover
0.16
Revenue / Total Assets
Equity Multiplier
1.43
Total Assets / Equity
Composite: -32.6% (reported: -32.6%)
Profitability
Liquidity
Current Ratio
3.29
Quick Ratio
3.22
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.16
Inventory Turnover
5.67
Days Sales Outstanding
35 days
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Earnings Quality
Accrual Ratio
-7.2%
-3.2pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.